Q32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test Results

Dow Jones

Dec 11, 2024

By Stephen Nakrosis

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.

The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B.

After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023.

Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss.

Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial.

Bempikibart was observed to be safe and well tolerated across both trials, the company said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 10, 2024 18:32 ET (23:32 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2490307328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490307328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490307328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 07:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490307328","market":"hk","top_or_hot":-1,"title":"Q32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart. \n</p>\n<p>\n  The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B. \n</p>\n<p>\n  After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023. \n</p>\n<p>\n  Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss. \n</p>\n<p>\n  Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial. \n</p>\n<p>\n  Bempikibart was observed to be safe and well tolerated across both trials, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2024 18:32 ET (23:32 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Q32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQ32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-11 07:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart. \n</p>\n<p>\n  The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B. \n</p>\n<p>\n  After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023. \n</p>\n<p>\n  Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss. \n</p>\n<p>\n  Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial. \n</p>\n<p>\n  Bempikibart was observed to be safe and well tolerated across both trials, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2024 18:32 ET (23:32 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QTTB","symbol_name":"Q32 Bio Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490307328","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490307328","pubTimestamp":1733873520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B.After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023.Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss.Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial.Bempikibart was observed to be safe and well tolerated across both trials, the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QTTB":"Q32 Bio Inc.","BK4139":"生物科技"},"translate_title":"脱发药物Bempikibart测试结果公布后，Q32 Bio股价跌至新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTTB":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart. \n\n\n  The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B. \n\n\n  After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023. \n\n\n  Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss. \n\n\n  Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial. \n\n\n  Bempikibart was observed to be safe and well tolerated across both trials, the company said. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 18:32 ET (23:32 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}